Investigational drugs under development for the treatment of PTSD

Expert Opinion on Investigational Drugs

Volumn 24, Issue 5, 2015, Pages 659-672

  Ragen, Benjamin J ^a   Seidel, Jordan ^a   Chollak, Christine ^a   Pietrzak, Robert H ^b,c   Neumeister, Alexander ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Evidence based; Neurobiology; Posttraumatic stress disorder; Treatment

Indexed keywords

ANXIOLYTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABINOID; CANNABINOID 1 RECEPTOR AGONIST; FATTY ACID AMIDASE INHIBITOR; GLUTAMIC ACID; OPIATE; OXYTOCIN; NEW DRUG;

DRUG RESEARCH; DSM-IV; EVIDENCE BASED MEDICINE; HUMAN; IN VIVO STUDY; NEUROIMAGING; PERSONALIZED MEDICINE; PHARMACEUTICAL CARE; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; POSTTRAUMATIC STRESS DISORDER; REVIEW; ANIMAL; DRUG DESIGN; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; STRESS DISORDERS, POST-TRAUMATIC;

ANIMALS; DRUG DESIGN; DRUGS, INVESTIGATIONAL; EVIDENCE-BASED MEDICINE; HUMANS; MOLECULAR TARGETED THERAPY; PHENOTYPE; PRECISION MEDICINE; STRESS DISORDERS, POST-TRAUMATIC;

EID: 84927603073     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1020109     Document Type: Review

References (165)

1. Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995;52(12):1048-60
2. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62(6):617-27
3. Pietrzak RH, Goldstein RB, Southwick SM, et al. Prevalence and axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Anxiety Disord 2011;25(3):456-65
4. Thomas JL, Wilk JE, Riviere LA, et al. Prevalence of mental health problems and functional impairment among active component and National Guard soldiers 3 and 12 months following combat in Iraq. Arch Gen Psychiatry 2010;67(6):614-23
5. Nishith P, Duntley SP, Domitrovich PP, et al. Effect of cognitive behavioral therapy on heart rate variability during REM sleep in female rape victims with PTSD. J Trauma Stress 2003;16(3):247-50
6. Brewin CR, Andrews B, Valentine JD. Meta-analysis of risk factors for posttraumatic stress disorder in traumaexposed adults. J Consult Clin Psychol 2000;68(5):748-66
7. Cloitre M, Garvert DW, Brewin CR, et al. Evidence for proposed ICD-11 PTSD and complex PTSD: a latent profile analysis. Eur J Psychotraumatol 2013;4
8. Breslau N, Lucia VC, Davis GC. Partial PTSD versus full PTSD: an empirical examination of associated impairment. Psychol Med 2004;34(7):1205-14
9. Ayer LA, Cisler JM, Danielson CK, et al. Adolescent posttraumatic stress disorder: an examination of factor structure reliability in two national samples. J Anxiety Disord 2011;25(3):411-21
10. Maguen S, Madden E, Bosch J, et al. Killing and latent classes of PTSD symptoms in Iraq and Afghanistan veterans. J Affect Disord 2013;145(3):344-8
11. Miller MW, Wolf EJ, Martin E, et al. Structural equation modeling of associations among combat exposure, PTSD symptom factors, and Global Assessment of Functioning. J Rehabil Res Dev 2008;45(3):359-69
12. Fontana A, Rosenheck R. Duty-related and sexual stress in the etiology of PTSD among women veterans who seek treatment. Psychiatr Serv 1998;49(5):658-62
13. Himmelfarb N, Yaeger D, Mintz J. Posttraumatic stress disorder in female veterans with military and civilian sexual trauma. J Trauma Stress 2006;19(6):837-46
14. First MB, Spitzer RL, Gibbons M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. New York State Psychiatric Institute, Biometrics Research, New York 1995
15. Simms LJ, Watson D, Doebbeling BN. Confirmatory factor analyses of posttraumatic stress symptoms in deployed and nondeployed veterans of the Gulf War. J Abnorm Psychol 2002;111(4):637-47
16. King DW, Leskin GA, King LA, et al. Confirmatory factor analysis of the Clinician-Administered PTSD Scale: evidence for the dimensionality of posttraumatic stress disorder. Psychol Assess 1998;10(2):90-6
17. Tsai J, Whealin JM, Scott JC, et al. Examining the relation between combatrelated concussion, a novel 5-factor model of posttraumatic stress symptoms, and health-related quality of life in Iraq and Afghanistan veterans. J Clin Psychiatry 2012;73(8):1110-18
18. Pietrzak RH, Tsai J, Harpaz-Rotem I, et al. Support for a novel five-factor model of posttraumatic stress symptoms in three independent samples of Iraq/ Afghanistan veterans: a confirmatory factor analytic study. J Psychiatr Res 2012;46(3):317-22
19. Harpaz-Rotem I, Tsai J, Pietrzak RH, et al. The dimensional structure of posttraumatic stress symptomatology in 323,903 U.S. veterans. J Psychiatr Res 2014;49:31-6
20. Armour C, Carragher N, Elhai JD. Assessing the fit of the Dysphoric Arousal model across two nationally representative epidemiological surveys: the Australian NSMHWB and the United States NESARC. J Anxiety Disord 2012;27(1):109-15
21. Elhai JD, Biehn TL, Armour C, et al. Evidence for a unique PTSD construct represented by PTSD's D1-D3 symptoms. J Anxiety Disord 2011;25(3):340-5
22. Contractor AA, Durham TA, Brennan JA, et al. DSM-5 PTSD's symptom dimensions and relations with major depression's symptom dimensions in a primary care sample. Psychiatry Res 2014;215(1):146-53
23. Tsai J, Harpaz-Rotem I, Armour C, et al. Dimensional structure of DSM-5 posttraumatic stress symptoms: results from the National Health and Resilience in Veterans Study. J Clin Psychiatry 2014. [Epub ahead of print]
24. Ginzburg K, Ein-Dor T, Solomon Z. Comorbidity of posttraumatic stress disorder, anxiety and depression: a 20-year longitudinal study of war veterans. J Affect Disord 2010;123(1-3):249-57
25. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
26. Hamilton M. The assessment of anxiety states by rating. Br J Psychiatry 1959;32:50-5
27. Renthal W, Maze I, Krishnan V, et al. Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron 2007;56(3):517-29
28. Hegadoren KM, O'Donnell T, Lanius R, et al. The role of beta-endorphin in the pathophysiology of major depression. Neuropeptides 2009;43(5):341-53
29. Forbes D, Lockwood E, Elhai JD, et al. An examination of the structure of posttraumatic stress disorder in relation to the anxiety and depressive disorders. J Affect Disord 2011;132(1-2):165-72
30. Pietrzak RH, Gallezot JD, Ding YS, et al. Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus. JAMA Psychiatry 2013;70(11):1199-205
31. Pietrzak RH, Henry S, Southwick SM, et al. Linking in vivo brain serotonin type 1B receptor density to phenotypic heterogeneity of posttraumatic stress symptomatology. Mol Psychiatry 2013;18(4):399-401
32. Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med 2013;11:8
33. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001;22(11):565-72
34. Andero R, Daviu N, Escorihuela RM, et al. 7,8-dihydroxyflavone, a TrkB receptor agonist, blocks long-term spatial memory impairment caused by immobilization stress in rats. Hippocampus 2012;22(3):399-408
35. Svizenska I, Dubovy P, Sulcova A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures - a short review. Pharmacol Biochem Behav 2008;90(4):501-11
36. Neumeister A, Normandin MD, Pietrzak RH, et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry 2013;18(9):1034-40
37. Hill MN, Bierer LM, Makotkine I, et al. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks. Psychoneuroendocrinology 2013;38(12):2952-61
38. Pietrzak RH, Huang Y, Corsi-Travali S, et al. Cannabinoid type 1 receptor availability in the amygdala mediates threat processing in trauma survivors. Neuropsychopharmacology 2014;39(11):2519-28
39. Germain A. Sleep disturbances as the hallmark of PTSD: where are we now? Am J Psychiatry 2013;170(4):372-82
40. Budney AJ, Hughes JR, Moore BA, et al. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004;161(11):1967-77
41. Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther 2009;15(1):84-8
42. Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol 2014;34(5):559-64
43. Jetly R, Heber A, Fraser GA, et al. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSDassociated nightmare: a preliminary tandomized, double-blind, placebocontrolled cross-over design study. Psychoneuroendocrinology 2015;51:585-8
44. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999;58(4):315-48
45. Bonn-Miller MO, Babson KA, Vandrey R. Using cannabis to help you sleep: heightened frequency of medical cannabis use among those with PTSD. Drug Alcohol Depend 2014;136:162-5
46. Roitman P, Mechoulam R, Cooper-Kazaz R, et al. Preliminary, open-label, pilot study of add-on oral delta(9)-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig 2014;34(8):587-91
47. Rothbaum BO, Davis M. Applying learning principles to the treatment of post-trauma reactions. In: King JA, Ferris CF, Lederhendler II, editors. Roots of mental illness in children. New York Acad Sciences; New York: 2003. p. 112-21
48. Rothbaum BO, Schwartz AC. Exposure therapy for Posttraumatic stress disorder. Am J Psychother 2002;56(1):59-75
49. Chhatwal JP, Ressler KJ. Modulation of fear and anxiety by the endogenous cannabinoid system. CNS Spectr 2007;12(3):211-20
50. Rabinak CA, Angstadt M, Lyons M, et al. Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans. Neurobiol Learn Mem 2014;113:125-34
51. Rabinak CA, Angstadt M, Sripada CS, et al. Cannabinoid facilitation of fear extinction memory recall in humans. Neuropharmacology 2013;64:396-402
52. Petrosino S, Di Marzo V. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs 2010;11(1):51-62
53. Gunduz-Cinar O, Hill MN, McEwen BS, et al. Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci 2013;34(11):637-44
54. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of clonef cDNA Nature. 1990;346(6284):561-4
55. Munro S, Thomas KL, Abushaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365(6441):61-5
56. Neumeister A, Normandin MD, Pietrzak RH, et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry 2013;18(9):1034-40
57. Gunduz-Cinar O, MacPherson KP, Cinar R, et al. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry 2013;18(7):813-23
58. Roberts CJ, Stuhr KL, Hutz MJ, et al. Endocannabinoid signaling in hypothalamic-pituitary-adrenocortical axis recovery following stress: effects of indirect agonists and comparison of male and female mice. Pharmacol Biochem Behav 2014;117:17-24
59. Garcia-Garcia F, Acosta-Pena E, Venebra-Munoz A, et al. Sleep-inducing factors. CNS Neurol Disord Drug Targets 2009;8(4):235-44
60. Kirilly E, Hunyady L, Bagdy G. Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB(1) receptor antagonists. J Neural Transm 2013;120(1):177-86
61. Geuze E, Westenberg HG, Jochims A, et al. Altered pain processing in veterans with posttraumatic stress disorder. Arch Gen Psychiatry 2007;64(1):76-85
62. Lindqvist D, Wolkowitz OM, Mellon S, et al. Proinflammatory milieu in combatrelated PTSD is independent of depression and early life stress. Brain Behav Immun 2014;42:81-8
63. Kraus A, Geuze E, Schmahl C, et al. Differentiation of pain ratings in combat-related posttraumatic stress disorder. Pain 2009;143(3):179-85
64. Eraly SA, Nievergelt CM, Maihofer AX, et al. Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk. JAMA Psychiatry 2014;71(4):423-31
65. Volkow ND, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med 2014;371(9):879
66. Pertwee RG. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 2008;13(2):147-59
67. Gobbi G, Bambico FR, Mangieri R, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 2005;102(51):18620-5
68. Justinova Z, Mangieri RA, Bortolato M, et al. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry 2008;64(11):930-7
69. Panlilio LV, Justinova Z, Goldberg SR. Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. Pharmacol Ther 2013;138(1):84-102
70. Godlewski G, Alapafuja SO, Batkai S, et al. Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects. Chem Biol 2010;17(11):1256-66
71. Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003;9(1):76-81
72. Di Marzo V, Fontana A, Cadas H, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994;372(6507):686-91
73. Zhang D, Saraf A, Kolasa T, et al. Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets. Neuropharmacology 2007;52(4):1095-105
74. Cravatt BF, Giang DK, Mayfield SP, et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996;384(6604):83-7
75. Pillarisetti S, Alexander CW, Khanna I. Pain and beyond: fatty acid amides and fatty acid amide hydrolase inhibitors in cardiovascular and metabolic diseases. Drug Discov Today 2009;14(23-24):1098-111
76. Hertzog DL. Recent advances in the cannabinoids. Expert Opin Ther Patents 2004;14(10):1435-52
77. Boger DL, Sato H, Lerner AE, et al. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci USA 2000;97(10):5044-9
78. Otrubova K, Ezzili C, Boger DL. The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH). Bioorg Med Chem Lett 2011;21(16):4674-85
79. Piomelli D, Tarzia G, Duranti A, et al. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 2006;12(1):21-38
80. Gunduz-Cinar O, MacPherson KP, Cinar R, et al. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry 2013;18(7):813-23
81. Moreira FA, Kaiser N, Monory K, et al. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoiddegrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 2008;54(1):141-50
82. Bortolato M, Mangieri RA, Fu J, et al. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 2007;62(10):1103-10
83. Varvel SA, Wise LE, Niyuhire F, et al. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology 2007;32(5):1032-41
84. Naidu PS, Varvel SA, Ahn K, et al. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 2007;192(1):61-70
85. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science 1992;258(5082):597-603
86. Myers KM, Carlezon WA, Davis M. Glutamate receptors in extinction and extinction-based therapies for psychiatric illness. Neuropsychopharmacology 2011;36(1):274-93
87. Walker DL, Ressler KJ, Lu KT, et al. Facilitation of conditioned fear extinction by systemic administration or intraamygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci 2002;22(6):2343-51
88. Rodrigues H, Figueira I, Lopes A, et al. Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis. PLoS One 2014;9(7):12
89. Attari A, Rajabi F, Maracy MR. D-cycloserine for treatment of numbing and avoidance in chronic post traumatic stress disorder: a randomized, double blind, clinical trial. J Res Med Sci 2014;19(7):592-8
90. Heresco-Levy U, Kremer I, Javitt DC, et al. Pilot-controlled trial of D-cycloserine for the treatment of posttraumatic stress disorder. Int J Neuropsychopharmacol 2002;5(4):301-7
91. Litz BT, Salters-Pedneault K, Steenkamp MM, et al. A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res 2012;46(9):1184-90
92. de Kleine RA, Hendriks GJ, Kusters WJC, et al. A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol Psychiatry 2012;71(11):962-8
93. Rothbaum BO, Price M, Jovanovic T, et al. A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in iraq and afghanistan war veterans. Am J Psychiatry 2014;171(6):640-8
94. Difede J, Cukor J, Wyka K, et al. D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial. Neuropsychopharmacology 2014;39(5):1052-8
95. Womble AL. Effects of ketamine on major depressive disorder in a patient with posttraumatic stress disorder. AANA J 2013;81(2):118-19
96. D'Andrea D, Andrew Sewell R. Transient resolution of treatmentresistant posttraumatic stress disorder following ketamine infusion. Biol Psychiatry 2013;74(9):e13-14
97. McGhee LL, Maani CV, Garza TH, et al. The intraoperative administration of ketamine to burned U.S. service members does not increase the incidence of post-traumatic stress disorder. Mil Med 2014;179(8 Suppl):41-6
98. Feder A, Parides MK, Murrough JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 2014;71(6):681-8
99. Schonenberg M, Reichwald U, Domes G, et al. Effects of peritraumatic ketamine medication on early and sustained posttraumatic stress symptoms in moderately injured accident victims. Psychopharmacology (Berl) 2005;182(3):420-5
100. Bagley J, Moghaddam B. Temporal dynamics of glutamate efflux in the prefrontal cortex and in the hippocampus following repeated stress: effects of pretreatment with saline or diazepam. Neuroscience 1997;77(1):65-73
101. Chambers RA, Bremner JD, Moghaddam B, et al. Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. Semin Clin Neuropsychiatry 1999;4(4):274-81
102. Singewald N, Zhou GY, Chen F, et al. Corticotropin-releasing factor modulates basal and stress-induced excitatory amino acid release in the locus coeruleus of conscious rats. Neurosci Lett 1996;204(1-2):45-8
103. Wright RA, Arnold MB, Wheeler WJ, et al. [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain. J Pharmacol Exp Ther 2001;298(2):453-60
104. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997;37:205-37
105. Schoepp DD, Jane DE, Monn JA. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999;38(10):1431-76
106. Li H, Weiss SR, Chuang DM, et al. Bidirectional synaptic plasticity in the rat basolateral amygdala: characterization of an activity-dependent switch sensitive to the presynaptic metabotropic glutamate receptor antagonist 2S-alpha-ethylglutamic acid. J Neurosci 1998;18(5):1662-70
107. Kerr AM, Capogna M. Unitary IPSPs enhance hilar mossy cell gain in the rat hippocampus. J Physiol 2007;578(Pt 2):451-70
108. Neale SA, Salt TE. Modulation of GABAergic inhibition in the rat superior colliculus by a presynaptic group II metabotropic glutamate receptor. J Physiol 2006;577(Pt 2):659-69
109. Price CJ, Karayannis T, Pal BZ, et al. Group II and III mGluRs-mediated presynaptic inhibition of EPSCs recorded from hippocampal interneurons of CA1 stratum lacunosum moleculare. Neuropharmacology 2005;49(Suppl 1):45-56
110. Turner JP, Salt TE. Group II and III metabotropic glutamate receptors and the control of the nucleus reticularis thalami input to rat thalamocortical neurones in vitro. Neuroscience 2003;122(2):459-69
111. Bradley SR, Marino MJ, Wittmann M, et al. Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia nigra pars reticulata. J Neurosci 2000;20(9):3085-94
112. Helton DR, Tizzano JP, Monn JA, et al. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 1998;284(2):651-60
113. Walker DL, Rattiner LM, Davis M. Group II metabotropic glutamate receptors within the amygdala regulate fear as assessed with potentiated startle in rats. Behav Neurosci 2002;116(6):1075-83
114. Walker DL, Davis M. The role of amygdala glutamate receptors in fear learning, fear-potentiated startle, and extinction. Pharmacol Biochem Behav 2002;71(3):379-92
115. Tizzano JP, Griffey KI, Schoepp DD. The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam. Pharmacol Biochem Behav 2002;73(2):367-74
116. Grillon C, Cordova J, Levine LR, et al. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl) 2003;168(4):446-54
117. Spooren WP, Schoeffter P, Gasparini F, et al. Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur J Pharmacol 2002;435(2-3):161-70
118. Monn JA, Valli MJ, Massey SM, et al. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo [3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 1997;40(4):528-37
119. Ferris P, Seward E, Dawson GR. Interactions between LY354740, a group II metabotropic agonist and the GABA (A)-benzodiazepine receptor complex in the rat elevated plus-maze. J Psychopharmacol 2001;15(2):76-82
120. Schoepp DD, Wright RA, Levine LR, et al. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 2003;6(3):189-97
121. Dunayevich E, Erickson J, Levine L, et al. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 2008;33(7):1603-10
122. Akil H, Watson SJ, Young E, et al. Endogenous opioids: biology and function. Annu Rev Neurosci 1984;7:223-55
123. Bruchas MR, Land BB, Chavkin C. The dynorphin/kappa opioid system as a modulator of stress-induced and proaddictive behaviors. Brain Res 2010;1314:44-55
124. Land BB, Bruchas MR, Lemos JC, et al. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci 2008;28(2):407-14
125. Shirayama Y, Ishida H, Iwata M, et al. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem 2004;90(5):1258-68
126. Simonin F, Gaveriaux-Ruff C, Befort K, et al. kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc Natl Acad Sci USA 1995;92(15):7006-10
127. Pietrzak RH, Naganawa M, Huang YY, et al. Association of in vivo k-opioid receptor availability and the transdiagnostic dimensional expression of trauma-related psychopathology. JAMA Psychiatry 2014;71(11):1262-70
128. Chen Y, Chen C, Wang Y, et al. Ligands regulate cell surface level of the human kappa opioid receptor by activationinduced down-regulation and pharmacological chaperone-mediated enhancement: differential effects of nonpeptide and peptide agonists. J Pharmacol Exp Ther 2006;319(2):765-75
129. Aldrich JV, McLaughlin JP. Peptide kappa opioid receptor ligands: potential for drug development. AAPS J 2009;11(2):312-22
130. Land BB, Bruchas MR, Schattauer S, et al. Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proc Natl Acad Sci USA 2009;106(45):19168-73
131. Munro TA, Berry LM, Van't Veer A, et al. Long-acting kappa opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity. BMC Pharmacol 2012;12:5
132. Negus SS, Mello NK, Linsenmayer DC, et al. Kappa opioid antagonist effects of the novel kappa antagonist 5'- guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys. Psychopharmacology (Berl) 2002;163(3-4):412-19
133. Resendez SL, Kuhnmuench M, Krzywosinski T, et al. kappa-Opioid receptors within the nucleus accumbens shell mediate pair bond maintenance. J Neurosci 2012;32(20):6771-84
134. Aldrich JV, Patkar KA, McLaughlin JP. Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action. Proc Natl Acad Sci USA 2009;106(43):18396-401
135. Peters J, Dieppa-Perea LM, Melendez LM, et al. Induction of fear extinction with hippocampal-infralimbic BDNF. Science 2010;328(5983):1288-90
136. Neumeister A, Corsi-Travali S, Green CR. The role of BDNF-TrkB signaling in the pathogenesis of PTSD. J Depress Anxiety 2013;6(S4):1-6
137. Shi SS, Shao SH, Yuan BP, et al. Acute stress and chronic stress change brainderived neurotrophic factor (BDNF) and tyrosine kinase-coupled receptor (TrkB) expression in both young and aged rat hippocampus. Yonsei Med J 2010;51(5):661-71
138. Heldt SA, Stanek L, Chhatwal JP, et al. Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. Mol Psychiatry 2007;12(7):656-70
139. Psotta L, Lessmann V, Endres T. Impaired fear extinction learning in adult heterozygous BDNF knock-out mice. Neurobiol Learn Mem 2013;103:34-8
140. Dell'Osso L, Carmassi C, Del Debbio A, et al. Brain-derived neurotrophic factor plasma levels in patients suffering from post-traumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009;33(5):899-902
141. Chen ZY, Jing DQ, Bath KG, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006;314(5796):140-3
142. Felmingham KL, Dobson-Stone C, Schofield PR, et al. The brain-derived neurotrophic factor Val66Met polymorphism predicts response to exposure therapy in posttraumatic stress disorder. Biol Psychiatry 2013;73(11):1059-63
143. Jang SW, Liu X, Yepes M, et al. A selective TrkB agonist with potent neurotrophic activities by 7,8- dihydroxyflavone. Proc Natl Acad Sci USA 2010;107(6):2687-92
144. Baker-Andresen D, Flavell CR, Li X, et al. Activation of BDNF signaling prevents the return of fear in female mice. Learn Mem 2013;20(5):237-40
145. Andero R, Heldt SA, Ye KQ, et al. Effect of 7,8-dihydroxyflavone, a smallmolecule TrkB agonist, on emotional learning. Am J Psychiatry 2011;168(2):163-72
146. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev 2001;81(2):629-83
147. Heinrichs M, Baumgartner T, Kirschbaum C, et al. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry 2003;54(12):1389-98
148. Woolley JD, Chuang B, Lam O, et al. Oxytocin administration enhances controlled social cognition in patients with schizophrenia. Psychoneuroendocrinology 2014;47:116-25
149. Preti A, Melis M, Siddi S, et al. Oxytocin and autism: a systematic review of randomized controlled trials. J Child Adolesc Psychopharmacol 2014;24(2):54-68
150. Feldman R, Vengrober A, Ebstein RP. Affiliation buffers stress: cumulative genetic risk in oxytocin-vasopressin genes combines with early caregiving to predict PTSD in war-exposed young children. Transl Psychiatry 2014;4:e370
151. Cohen H, Kaplan Z, Kozlovsky N, et al. Hippocampal microinfusion of oxytocin attenuates the behavioural response to stress by means of dynamic interplay with the glucocorticoid-catecholamine responses. J Neuroendocrinol 2010;22(8):889-904
152. Toth I, Neumann ID, Slattery DA. Central administration of oxytocin receptor ligands affects cued fear extinction in rats and mice in a timepoint-dependent manner. Psychopharmacology (Berl) 2012;223(2):149-58
153. Koch SB, van Zuiden M, Nawijn L, et al. Intranasal oxytocin as strategy for medication-enhanced psychotherapy of PTSD: salience processing and fear inhibition processes. Psychoneuroendocrinology 2014;40:242-56
154. Acheson D, Feifel D, de Wilde S, et al. The effect of intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample. Psychopharmacology (Berl) 2013;229(1):199-208
155. Frijling JL, van Zuiden M, Koch SB, et al. Efficacy of oxytocin administration early after psychotrauma in preventing the development of PTSD: study protocol of a randomized controlled trial. BMC Psychiatry 2014;14:92
156. Ipser JC, Stein DJ. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). Int J Neuropsychopharmacol 2012;15(6):825-40
157. Foa EB, Keane TM, Friedman MJ, et al. editors. Effective treatments for PTSD: practice guidelines from the international society for traumatic stress studies. The Guilford Press; New York, NY: 2009
158. Writer BW, Meyer EG, Schillerstrom JE. Prazosin for military combat-related PTSD nightmares: a critical review. J Neuropsychiatry Clin Neurosci 2014;26(1):24-33
159. Marshall GN, Schell TL, Glynn SM, et al. The role of hyperarousal in the manifestation of posttraumatic psychological distress following injury. J Abnorm Psychol 2006;115(3):624-8
160. Pietrzak RH, Feder A, Schechter CB, et al. Dimensional structure and course of post-traumatic stress symptomatology in World Trade Center responders. Psychol Med 2013;44:2085-98. doi:10.1017/S0033291713002924
161. Schell TL, Marshall GN, Jaycox LH. All symptoms are not created equal: the prominent role of hyperarousal in the natural course of posttraumatic psychological distress. J Abnorm Psychol 2004;113(2):189-97
162. Solomon Z, Horesh D, Ein-Dor T. The longitudinal course of posttraumatic stress disorder symptom clusters among war veterans. J Clin Psychiatry 2009;70(6):837-43
163. Davis MT, Witte TK, Weathers FW. Posttraumatic stress disorder and suicidal ideation: the role of specific symptoms within the framework of the interpersonal-psychological theory of suicide. Psychol Trauma 2014;6(6):610-18
164. Ramsawh HJ, Fullerton CS, Mash HBH, et al. Risk for suicidal behaviors associated with PTSD, depression, and their comorbidity in the US Army. J Affect Disord 2014;161:116-22
165. Sareen J, Cox BJ, Stein MB, et al. Physical and mental comorbidity, disability, and suicidal behavior associated with posttraumatic stress disorder in a large community sample. Psychosom Med 2007;69(3):242-8